Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 4 | Rare Historical Photos

Let These 3 Stocks Lead You Through the Bear Market

Gloomy earning guidance halted the S&P 500’s three-day winning streak. Moreover, a recession seems apparent as the U.S. economy battles sky-high inflation, aggressive rate hikes, and geopolitical headwinds. With the bear market not over yet, we think fundamentally strong stocks Walmart (WMT), Cisco Systems (CSCO), and Vertex Pharmaceuticals (VRTX) might…

StockNews.com

2 No-Brainer Biotech Stocks to Buy Right Now and 1 to Sell

The biotech industry is set to benefit from continued investments in breakthrough developments and federal support. Against this backdrop, fundamentally strong biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) could be solid buys. However, Relmada Therapeutics (RLMD) might be best avoided considering its weak fundamentals. Read on….

StockNews.com

2 Top Biotech Stocks to Buy for the Long Haul and 1 to Sell

Government initiatives to expand domestic biotech production and research and rising private investments in advancing technologies are expected to boost the industry’s prospects. While we believe biotech stocks Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) could be ideal investments for the long run, fundamentally weak Timber Pharmaceuticals (TMBR) might be best…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Stocks to Ride the Bear Market Rally

Stocks could be embarking on another bear market rally despite a plethora of challenges. One factor is we are entering a seasonally bullish period of the year. Another is the bullish technical setup following the undercut and recovery of the mid-June lows. 3 stocks that investors should consider buying to…

StockNews.com

Minerva Neurosciences up More Than 100% This Week, but Is It a Better Pick Than Vertex Pharma?

Minerva Neurosciences (NERV) and Vertex Pharmaceuticals (VRTX) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the industry. Since NERV has gained more than 100% this week, is it a better investment than VRTX? Read more to find out….

StockNews.com

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

This Biotech Breakout Star is Our Growth Stock of the Week

Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Stocks to Buy With Rising Recession Risk, Increasing Geopolitical Tensions

Despite the bear market rally, the market is facing serious risks due to rising recession risk and increasing geopolitical tensions. Here are 3 defensive picks to help investors outperform in this tricky environment: Lockheed Martin (LMT), Vertex Pharmaceuticals (VRTX), and Elevance Health (ELVH).

StockNews.com

1 Stock to Buy This Week and 1 Stock to Dump

Investors’ sentiment is significantly mixed at the moment, with market volatility at its peak. It could be wise to buy quality stock Vertex Pharmaceuticals (VRTX), which possesses robust financials. However, fundamentally weak stock NeoGenomics (NEO) is best avoided now. Read on….

StockNews.com

4 Stocks That Are Long-Term Winners

In an uncertain market environment, investors must look for stocks that could win in the long run based on their strong fundamentals and solid growth prospects. We think Walmart (WMT), Tennant (TNC), Commvault Systems (CVLT), and Vertex Pharmaceuticals (VRTX) could be good choices on that front. Read on to learn…

StockNews.com

Don't Rule out a Summer Rally for This 1 Biotech Stock

Leading biotechnology company Vertex Pharmaceuticals (VRTX) has achieved strong top and bottom-line growth in its last quarter. Furthermore, the company is well-positioned to benefit from its diversified pipeline of transformative small-molecule, cell, and genetic therapies. Thus, even after gaining 27.5% year-to-date, we think VRTX still has decent upside potential. Read…

StockNews.com

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

StockNews.com

2 Stocks That Are Primed to Outperform in the Next Bull Market

Bear markets clear out the excesses of bull markets, transform greed into fear, and lead to attractive valuations. Bear markets can also help us identify the next batch of winning stocks that will go on to deliver massive returns. One commonality between these winning stocks is continued business and/or financial…

StockNews.com

4 "Strong Buy" Biotech Stocks to Add to Your Watchlist

As the Biotech industry’s role in finding cures for chronic diseases and critical conditions is expected to keep attracting investors’ attention, it could be wise to scoop up shares of the fundamentally-strong biotech companies Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR), Amgen (AMGN), and Sino Biopharmaceutical (SBHMY) because of their solid…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 High-Quality Stocks to Buy Right Now

The jitters over inflation's impact on the economy’s growth prospects have lately led to immense stock market volatility. Since the macroeconomic headwinds are not expected to ease anytime soon, we think it could be wise to invest in high-quality stocks Vertex Pharmaceuticals (VRTX), United Microelectronics (UMC), and Sanderson Farms (SAFM),…

StockNews.com

5 "Strong Buy" Pharmaceutical Stocks to Own for the Long Haul

The inelastic demand and rising investments in research and development should drive the pharmaceutical industry’s growth in the long run. Therefore, pharmaceutical stocks AbbVie (ABBV), Amgen (AMGN), Catalyst (CPRX), Novo Nordisk (NVO), and Vertex (VRTX), which possess sound fundamentals, could be solid long-term investments. These stocks are rated Strong Buy…

StockNews.com

VRTX is the Growth Stock of the Week

The market is in a tough place with stubbornly high inflation, a hawkish Fed, and a slowing economy. These conditions are tough for most stocks, but pharmaceuticals are an exception. One of the top companies in the space is Vertex Pharmaceuticals (VRTX). Read on to find out why it's our…

StockNews.com

3 Stocks Rated ‘Strong-Buy’ For June 2022

Although investors remain anxious about the possibility of a recession, the Fed is optimistic about a “soft landing.” However, given the volatile backdrop, we think quality stocks Vertex Pharmaceuticals (VRTX), McKesson (MCK), and APA (APA), which are rated ‘Strong Buy’ in our proprietary rating system, could be ideal additions to…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.

Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 4.83% on an annualized basis producing an average annual return of 16.83%. Currently, Vertex Pharmaceuticals has a market capitalization of $68.84 billion.

StockNews.com

2 Recession Stocks to Buy Right Now

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

StockNews.com

1 Biotech Stock to Buy and 1 to Sell

Increasing investments in R&D to develop new therapies, rising cases of chronic diseases, and an aging population should drive the biotech market’s growth. Therefore, we think it could be wise to invest in the shares of fundamentally sound biotech company Vertex Pharmaceuticals (VRTX). Conversely, we think the shares of Galmed…

Benzinga

Analyst Ratings for Vertex Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 17.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $65.74 billion.

Benzinga

Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial Put On Hold

The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) VX-880 Phase 1/2 study due to a determination that there is insufficient information to support dose escalation with the product. VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for type 1 diabetes (T1D). Three patients have been…

1 2 3 4 5

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Jaimini DesaiJaimini

62 stories

Jaimini DesaiJaimini Desai

59 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.